comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 23:02:07 - browse：8

Biogen announced a new round of cost cuts Tuesday, saying that it plans to save $700 million in operating costs and cut 1,000 jobs by 2025.

The company also released second quarter sales and earnings that handily topped the forecasts of Wall Street analysts. In early morning trading, Biogen shares rose more than 1%.

Biogen is attempting to recover from a series of corporate stumbles, the biggest of which involved the development and launch of the Alzheimer’s drug Aduhelm. The medicine was the first of a new class of disease-modifying Alzheimer’s drugs to be approved by the Food and Drug Administration. But doubts about the quality of the data behind the medicine meant that Medicare wouldn’t pay for it and doctors did not prescribe it. The resulting financial disaster cleaned out Biogen’s executive suite.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Readers discuss the intersection of pregnancy and addiction

focus

WSS

Cigna wins case to block Amy Bricker's move to CVS

'Essentially witchcraft:' A former naturopath takes on the field

Stigma and the return of syphilis

Scientists successfully use ultrasound imaging to map brain activity

What will save rural psychiatry services? Higher Medicaid payments

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

focus

comprehensive

focus

United colonoscopy coverage change 'may cost lives,' doctors say

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

In age of alternative facts, a scholarly course on calling out crap

Adam's Biotech Scorecard: Do Sarepta's exon

Medicare details structure of new drug price negotiation program

Deposition: Sackler embraced plan to conceal OxyContin’s strength

How one medical school became remarkably diverse

Biohaven protein

Activists slam private health insurers over coverage restrictions

Insmed lung disease drug hits target in key Phase 3 trial

focus

Health care court cases: Humana, Sutter, Novant

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Prosthetic arm enables patients to feel the objects they grip

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Latest bird flu infection made farmworker sicker than earlier cases

5 takeaways from STAT's examination of Zynex Medical

focus

hotspot

entertainment

hotspot